Stimuli-sensitive nanoparticles for multiple anti-HIV microbicides
Source abstract
Abstract
This study is aimed to develop and evaluate an advanced intravaginal formulation for the delivery of multiple anti-HIV microbicides. Novel stimuli-sensitive nanoparticles (NPs) which protected the encapsulated drugs from being degraded in acidic pH conditions were made of Eudragit S-100® (ES100®), a pH-sensitive polymer. ES100® NPs were prepared using the quasi-emulsion solvent diffusion technique and loaded with two microbicides namely Tenofovir (TNF) and Etravirine (ETV). The effects of various fabrication parameters on the formulation properties were evaluated for the optimization of ES100® NPs. The morphology of the ES100® NPs was examined by scanning electron microscopy. The cytotoxicity of NPs containing microbicides individually or in a combination was assessed using cell viability and trans-epithelial electrical resistance (TEER) measurements. The cellular uptake rates of the model microbicides by human vaginal epithelial cells, VK2 E6/E7 cells, were evaluated using confocal microscopy and florescence-assisted cell sorting technique. ES100® NPs had a spherical shape, smooth surface, and uniform texture with a little aggregation. The average particle size for NPs loaded with TNF ranged from 125 to 230 nm, whereas those for ETV-loaded NPs ranged from 160 to 280 nm. ES100® NPs had zeta potential in the range of −5 to −10 mV. In-vitro release studies displayed the potential benefits of ES100® NPs in retaining and protecting the loaded microbicides at vaginal pH (acidic), but immediately releasing them as the pH changes to neutral or 7.4 (physiological pH). Cell viability studies demonstrated that ES100® NPs did not exert any cytotoxicity individually or in a combination of both microbicides. TEER measurements confirmed that ES100® NPs loaded with TNF and ETV did not cause any changes in the barrier integrity of VK2 E6/E7 cell monolayer. The cellular uptake study revealed that ES100® NPs were taken by vaginal epithelial cells through the endocytosis process and that the uptake rate of the model microbicides loaded in nanoparticles was greater than that in the solution. The ES100® NPs whose degradation rates are dependent on environmental pH would serve as an efficient platform for targeted delivery of multiple microbicides to protect women from sexually transmitted diseases including HIV-1 infection.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: HIV/AIDS Research and Interventions · Advanced Drug Delivery Systems · Reproductive tract infections research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Ahmad M, Akhtar N, Murtaza G, Hussain SW (2012) Formulation development and in vitro evaluation of theophylline microcapsules. Pak J Pharm Sci 25(1):15–19
2. Astete CE, Sabliov CM (2006) Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 17(3):247–28910.1163/156856206775997322 ↗
3. Asvadi NH, Dang NT, Davis-Poynter N, Coombes AG (2013) Evaluation of microporous polycaprolactone matrices for controlled delivery of antiviral microbicides to the female genital tract. J Mater Sci Mater Med 24(12):2719–272710.1007/s10856-013-5010-6 ↗
4. Chaowanachan T, Krogstad E, Ball C, Woodrow KA (2013) Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS ONE 8(4):e6141610.1371/journal.pone.0061416 ↗
5. Chen S, Einspanier R, Schoen J (2015) Transepithelial electrical resistance (TEER): a functional parameter to monitor the quality of oviduct epithelial cells cultured on filter supports. Histochem Cell Biol 144(5):509–51510.1007/s00418-015-1351-1 ↗
6. Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX (2004) Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol 10(12):1769–177410.3748/wjg.v10.i12.1769 ↗
7. Degim IT, Tugcu-Demiroz F, Tamer-Ilbasmis S, Acarturk F (2008) Development of controlled release sildenafil formulations for vaginal administration. Drug Deliv 15(4):259–26510.1080/10717540802006781 ↗
8. Duarte AR, Roy C, Vega-Gonzalez A, Duarte CM, Subra-Paternault P (2007) Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int J Pharm 332:132–13910.1016/j.ijpharm.2006.09.041 ↗
9. Emau P, Jiang Y, Agy MB, Tian B, Bekele G, Tsai CC (2006) Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention. AIDS Res Ther 3:2910.1186/1742-6405-3-29 ↗
10. Freeling JP, Koehn J, Shu C, Sun J, Ho RJ (2015) Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses 31(1):107–11410.1089/aid.2014.0210 ↗
11. Galindo CL, Fadl AA, Sha J, Gutierrez C, Popov VL, Boldogh I, Aggarwal BB, Chopra AK (2004) Aeromonas hydrophila cytotoxic enterotoxin activates mitogen-activated protein kinases and induces apoptosis in murine macrophages and human intestinal epithelial cells. J Biol Chem 279:37597–3761210.1074/jbc.M404641200 ↗
12. Hu D, Liu L, Chen W, Li S, Zhao Y (2012) A novel preparation method for 5-aminosalicylic acid loaded Eudragit S100 nanoparticles. Int J Mol Sci 13(5):6454–646810.3390/ijms13056454 ↗
13. Hughes PJ, Cretton-Scott E, Teague A, Wensel TM (2011) Protease inhibitors for patients with HIV-1 infection: a comparative overview. PT 36(6):332–345
14. Kawashima Y, Niwa T, Handa T, Takeuchi H, Iwamoto T, Itoh K (1989) Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J Pharm Sci 78(1):68–7210.1002/jps.2600780118 ↗
15. Khan MZ, Prebeg Z, Kurjakovic N (1999) A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Release 58(2):215–22210.1016/S0168-3659(98)00151-5 ↗
16. Khan MZ, Stedul HP, Kurjakovic N (2000) A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit L100 and Eudragit S100 combinations. Drug Dev Ind Pharm 26(5):549–55410.1081/DDC-100101266 ↗
17. Kinch MS, Patridge E (2014) An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. Drug Discov Today 19(10):1510–151310.1016/j.drudis.2014.05.012 ↗
18. Kiser PF, Mesquita PM, Herold BC (2012) A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses 28(11):1373–137810.1089/aid.2012.0277 ↗
19. Krakower DS (2015) Current topics in microbiology and immunology: microbicides for prevention of HIV infection. Clin Infect Dis 60(11):173510.1093/cid/civ147 ↗
20. Lee CH, Giri N (2014) Design of stimuli-sensitive microbicide formulations. In: Neves JD, Sarmento B (eds) Drug delivery and development of anti HIV microbicides, 1st edn. Pan Stanford, Singapur, pp 377–414
21. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC (2005) Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 49(5):1898–190610.1128/AAC.49.5.1898-1906.2005 ↗
22. Lehman KOR (1989) Chemistry and application properties of polymethacrylate coating systems. In: McGinity JW (ed) Aqueous polymeric coating for pharmaceutical dosage forms. Marcel Dekker, New York, p 153
23. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezar IJ, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B, DUET-1 Study Group (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370(9581):29–3810.1016/S0140-6736(07)61047-2 ↗
24. Malinova V, Kind L, Grzelakowski M, Meier W (2010) Strategies for triggered release from polymer-based nanostructures: medical applications, 1st edn. Royal Society of Chemistry, Cambridge, pp 16–80
25. Marin E, Briceno MI, Caballero-George C (2013) Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine 8:3071–3090
26. Mehta R, Chawla A, Sharma P, Pawar P (2013) Formulation and in vitro evaluation of Eudragit S-100 coated naproxen matrix tablets for colon-targeted drug delivery system. J Adv Pharm Technol Res 4(1):31–4110.4103/2231-4040.107498 ↗
27. Mellaerts R, Fayad EJ, Van den Mooter G, Augustijns P, Rivallan M, Thibault-Starzyk F, Martens JA (2013) In situ FT-IR investigation of etravirine speciation in pores of SBA-15 ordered mesoporous silica material upon contact with water. Mol Pharm 10(2):567–57310.1021/mp300229q ↗
28. Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for drug delivery. Nat Mater 12(11):991–100310.1038/nmat3776 ↗
29. Nicol MR, Adams JL, Kashuba AD (2013) HIV PrEP trials: the road to success. Clin Investig 3(3). doi: 10.4155/cli.12.15510.4155/cli.12.155 ↗
30. Nikoopour E, Singh B (2014) Reciprocity in microbiome and immune system interactions and its implications in disease and health. Inflamm Allergy Drug Targets 13(2):94–10410.2174/1871528113666140330201056 ↗
31. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G (2002) Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16(1–2):53–6110.1016/S0928-0987(02)00057-X ↗
32. Ramkumar GR, Srinivasan S, Bhoopathy TJ, Gunasekaran S (2013) Vibrational spectroscopic studies of tenofovir using density functional theory method. J Chem 1–12. doi: 10.1155/2013/12650210.1155/2013/126502 ↗
33. Scherrer AU, Hasse B, Von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Bucher HC, Ledergerber B, Gunthard HF (2009) Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Med 10(10):647–65610.1111/j.1468-1293.2009.00756.x ↗
34. Shalaby KS, Soliman ME, Casettari L, Bonacucina G, Cespi M, Palmieri GF, Sammour OA, El Shamy AA (2014) Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks. Int J Nanomedicine 9:4953–4964
35. Sidibé M (2012). UNAIDS report on the global AIDS epidemic. M. Sidibé
36. Sinha B, Muller RH, Moschwitzer JP (2013) Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm 453(1):126–14110.1016/j.ijpharm.2013.01.019 ↗
37. Tipre D, Vavia P (2003) Acrylate-based transdermal therapeutic system of nitrendipine. Polym Adv Technol 14(7):502–50710.1002/pat.361 ↗
38. Treuel L, Jiang X, Nienhaus GU (2013) New views on cellular uptake and trafficking of manufactured nanoparticles. J R Soc Interface 10(82):2012093910.1098/rsif.2012.0939 ↗
39. Usach I, Melis V, Peris JE (2013) Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J Int AIDS Soc 16:1–1410.7448/IAS.16.1.18567 ↗
40. Vermund SH, Leigh-Brown AJ (2012) The HIV epidemic: high-income countries. Cold Spring Harb Perspect Med 2(5):a00719510.1101/cshperspect.a007195 ↗
41. Vranic S, Boggetto N, Contremoulins V, Mornet S, Reinhardt N, Marano F, Baeza-Squiban A, Boland S (2013) Deciphering the mechanisms of cellular uptake of engineered nanoparticles by accurate evaluation of internalization using imaging flow cytometry. Part Fibre Toxicol 10:210.1186/1743-8977-10-2 ↗
42. Wehrle P, Magenheim B, Benita S (1995) The Influence of process parameters on the PLA nanoparticle size distribution evaluated by means of factorial design. EurJ Pharm Biopharm 41:19–26
43. Weuts I, Van Dycke F, Voorspoels J, De Cort S, Stokbroekx S, Leemans R, Brewster ME, Xu D, Segmuller B, Turner YT, Roberts CJ, Davies MC, Qi S, Craig DQ, Reading M (2011) Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine. J Pharm Sci 100(1):260–27410.1002/jps.22242 ↗
44. Yoo JW, Giri N, Lee CH (2011) pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharm 403(1–2):262–267
45. Zidan AS, Spinks C, Fortunak J, Habib M, Khan MA (2010) Near-infrared investigations of novel anti-HIV tenofovir liposomes. AAPS J 12(2):202–21410.1208/s12248-010-9177-1 ↗